CURRENT ISSUE FEATURED ARTICLES

Industry Explorers Blaze On: How The Journey To Entrepreneurial Biotech Begins

These are the stories of longtime leaders, still active in the industry, sharing their historical perspectives on innovation in the life sciences industry. This month: Why David Hale is considered and icon of entrepreneurial biotech.

More From Executive Interviews

ALSO IN THIS MONTH'S ISSUE

  • Warning: Don’t Let Bio-Euphoria Distract You From Being Disciplined
    Warning: Don’t Let Bio-Euphoria Distract You From Being Disciplined

    “Innovation should go well beyond the science and apply to all aspects of an organization’s operations.”

  • Rx Industry Fighting Off New Salvos To Extract Medicare Savings
    Rx Industry Fighting Off New Salvos To Extract Medicare Savings

    When the King v. Burwell verdict upholding the Obamacare subsidies was announced, Republicans in Congress breathed a collective sigh of relief. Yes, most of them thought the law was unconstitutional, and a clear reading of the statute that subsidies could only flow to an exchange “established by a State” caused flummoxed consternation. But they had dodged the bullet of what to do with the 7 million individuals receiving subsidies through the federal exchange who were about to lose their coverage.

  • Are We Truly Investing To Meet The World’s Unmet Medical Need?
    Are We Truly Investing To Meet The World’s Unmet Medical Need?

    A recent biopharmaceutical industry analysis by David Thomas and Chad Wessel (Emerging Therapeutic Company Investment and Deal Trends, June 2015) reveals that for the past decade oncology garners more investment than any other disease.

  • Why Is Takeda Focusing On Vaccines?
    Why Is Takeda Focusing On Vaccines?

    Succeeding in the vaccines business is not easy. Low margins and manufacturing challenges make it a difficult business for any pharma company. In fact, two large manufacturers, Baxter and Novartis, recently pulled the plug on their vaccine efforts. Four of the remaining sponsor companies, GSK, Merck, Pfizer, and Sanofi Pasteur, are formidable competitors. Despite the challenges that exist, Takeda decided in 2012 to enter this global market, building upon its 70-year history of Japanese vaccine business, with plans to be the world leader by the year 2020.

  • Building A Narrative: Develop Emotional Connections To Raise Capital
    Building A Narrative: Develop Emotional Connections To Raise Capital

    For 55 years, comedian Jerry Lewis hosted Labor Day Muscular Dystrophy Telethons featuring “Jerry’s Kids,” the poster children who made muscular dystrophy real for millions of Americans. By creating an emotional connection with the audience, those telethons raised more than $2 billion.

  • Alzheimer’s Drug Development: Not An Easy Path To Pursue
    Alzheimer’s Drug Development: Not An Easy Path To Pursue

    In the past decade, Alzheimer’s research has failed to produce a new drug addressing the progression of the disease, despite the resources invested in high-profile clinical trials.

  • Can Nano Bring Us Back From Personalized To Mass Medicine?
    Can Nano Bring Us Back From Personalized To Mass Medicine?

    How big can a singular change in perspective be? As big as a Copernican Revolution, you might say. Or more precisely, perhaps, how small can it be? If it’s the fundamental change that creates a metatheory moving biology to physics, it can be as small as building particles — or deconstructing them — atom-by-atom to bring new drugs to mankind. This is the big and small of nanomedicine (nano).

More Magazine Articles....

FROM THE CUTTING ROOM FLOOR

  • Celgene's M&A Dealer - “The Best Career Decision I Ever Made.”

    For George Golumbeski, the key to becoming good at BD is learning by doing. “I was once asked, ‘What books can one read to learn about negotiations?’” he says. “Forget it. You’ve got to get in there. Hopefully you have somebody who can show you the ropes. And, you are probably going to mess up a few times.” 

More...

LIFE SCEINCE TRAINING INSTITUTE COURSES

Monitoring Electronic Health Records (EHRs): Frequently Asked Questions

September 9, 2015
1pm-2:30pm EDT, Online Training

Root Cause Analysis for GCP – A Risk Action Plan Guide

September 22, 2015
1pm-3pm EDT, Online Training

CRO Oversight: Risk Assessment & Action Planning

October 6, 2015
1pm-2:30pm EDT, Online Training

FDA Guidance on Social Media: Questions Answered and Unanswered

October 13, 2015
1pm-2:30pm EDT, Online Training
More Upcoming Courses

VIEW THE DIGITAL EDITION

LIFE SCIENCE LEADER BLOGS

  • How A Twitter KOL List Can Keep Life Sciences Execs Focused
    How A Twitter KOL List Can Keep Life Sciences Execs Focused

    There are plenty of articles out there telling us who to follow on Twitter. For example, Twitter In The Life Sciences: The Ultimate ‘Who To Follow’ Checklist, Fast Company’s take on who the most creative people in business follow, Luke Timmerman’s suggestion on who life science pros should follow, 31 Influential Business Leaders To Follow On Twitter, Top Leadership Experts To Follow In 2015, and so on.

  • Will India Be The Downfall Of The U.S. Biopharma Industry?
    Will India Be The Downfall Of The U.S. Biopharma Industry?

    In September 2014, Gilead announced a generic licensing agreement with then seven India-based generic pharmaceutical manufacturers to increase access to Hepatitis C treatments in developing countries.

  • Are The Big Paydays For Unproven Biotechs A Concern?
    Are The Big Paydays For Unproven Biotechs A Concern?

    Last week, an article in the Wall Street Journal pointed to NantKwest Inc. (NASDAQ: NK) as being the latest example of a biotech company which is valued at several billion dollars even though it still doesn’t have an approved drug.

More From Life Science Leader Blogs

 UPCOMING EVENTS

Root Cause Analysis & CAPA Identification: A Step-by-Step Guide for Manufacturers

September 2, 2015
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!

Using Social Media for Patient Recruitment in Clinical Trials

September 3, 2015
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!

Monitoring Electronic Health Records (EHRs): Frequently Asked Questions

September 9, 2015
1pm-2:30pm EDT, Online Training

2015 Pharma CI USA Conference & Exhibition

September 10 - 11, 2015
Parsippany, NJ

Laboratory Data Integrity: Current Expectations for OOS Result Investigations

September 16, 2015
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
See All Events